This HTML5 document contains 108 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n28http://linked.opendata.cz/resource/drugbank/drug/DB01183/identifier/pubchem-substance/
n31http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n9http://linked.opendata.cz/resource/drugbank/drug/DB01183/identifier/kegg-drug/
n24http://linked.opendata.cz/resource/drugbank/drug/DB01183/identifier/iuphar/
n30http://linked.opendata.cz/resource/AHFS/
n21http://linked.opendata.cz/resource/drugbank/drug/DB01183/identifier/drugbank/
n12http://linked.opendata.cz/resource/mesh/concept/
n16http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n26http://linked.opendata.cz/resource/drugbank/drug/DB01183/identifier/guide-to-pharmacology/
n17http://linked.opendata.cz/resource/drugbank/dosage/
n15http://linked.opendata.cz/resource/drugbank/mixture/
n10http://linked.opendata.cz/resource/drugbank/drug/DB01183/identifier/national-drug-code-directory/
n14http://bio2rdf.org/drugbank:
n20http://linked.opendata.cz/resource/drugbank/drug/DB01183/identifier/chemspider/
admshttp://www.w3.org/ns/adms#
n23http://linked.opendata.cz/resource/drugbank/drug/DB01183/identifier/chebi/
n22http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n32http://linked.opendata.cz/resource/drugbank/medicinal-product/
n8http://linked.opendata.cz/resource/drugbank/drug/DB01183/identifier/wikipedia/
n11http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n29http://linked.opendata.cz/resource/drugbank/drug/DB01183/identifier/pharmgkb/
n6http://www.drugs.com/cdi/
n4http://linked.opendata.cz/resource/drugbank/property/
n25http://linked.opendata.cz/resource/drugbank/drug/DB01183/identifier/kegg-compound/
xsdhhttp://www.w3.org/2001/XMLSchema#
n27http://linked.opendata.cz/resource/drugbank/drug/DB01183/identifier/pubchem-compound/
n19http://linked.opendata.cz/resource/atc/
n18http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01183
rdf:type
n3:Drug
n3:description
A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors. [PubChem]
n3:dosage
n17:271B5067-363D-11E5-9242-09173F13E4C5 n17:271B5068-363D-11E5-9242-09173F13E4C5 n17:271B5069-363D-11E5-9242-09173F13E4C5 n17:271B5065-363D-11E5-9242-09173F13E4C5 n17:271B5066-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# FDA label # http://www.medscape.com/viewarticle/441915_3
n3:group
approved
n3:halfLife
Adults = 30-81 minutes; Neonates = 3.1 ± 0.5 hours.
n3:indication
For the complete or partial reversal of narcotic depression, including respiratory depression, induced by opioids including natural and synthetic narcotics, propoxyphene, methadone and the narcotic-antagonist analgesics: nalbuphine, pentazocine and butorphanol. It is also indicated for the diagnosis of suspected acute opioid overdose. It may also be used as an adjunctive agent to increase blood pressure in the management of septic shock.
owl:sameAs
n14:DB01183 n22:DB01183
dcterms:title
Naloxone
adms:identifier
n8:Naloxone n9:D08249 n10:0409-1782-69 n20:4447644 n21:DB01183 n23:7459 n24:1676 n25:C07252 n26:1676 n27:5284596 n28:46508816 n29:PA450586
n3:mechanismOfAction
While the mechanism of action of naloxone is not fully understood, the preponderance of evidence suggests that naloxone antagonizes the opioid effects by competing for the same receptor sites, especially the opioid mu receptor. Recently, naloxone has been shown to bind all three opioid receptors (mu, kappa and gamma) but the strongest binding is to the mu receptor.
n3:packager
n16:271B5053-363D-11E5-9242-09173F13E4C5 n16:271B5054-363D-11E5-9242-09173F13E4C5 n16:271B5051-363D-11E5-9242-09173F13E4C5 n16:271B5052-363D-11E5-9242-09173F13E4C5 n16:271B504F-363D-11E5-9242-09173F13E4C5 n16:271B5050-363D-11E5-9242-09173F13E4C5 n16:271B504E-363D-11E5-9242-09173F13E4C5 n16:271B5057-363D-11E5-9242-09173F13E4C5 n16:271B5058-363D-11E5-9242-09173F13E4C5 n16:271B5055-363D-11E5-9242-09173F13E4C5 n16:271B5056-363D-11E5-9242-09173F13E4C5 n16:271B505E-363D-11E5-9242-09173F13E4C5 n16:271B505F-363D-11E5-9242-09173F13E4C5 n16:271B505C-363D-11E5-9242-09173F13E4C5 n16:271B505D-363D-11E5-9242-09173F13E4C5 n16:271B505A-363D-11E5-9242-09173F13E4C5 n16:271B505B-363D-11E5-9242-09173F13E4C5 n16:271B5059-363D-11E5-9242-09173F13E4C5 n16:271B504D-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Urine (25%- 40% is excreted as metabolites within 6 hours)
n3:synonym
N-Allylnoroxymorphone EN 1530 Base 1-N-Allyl-14-hydroxynordihydromorphinone Naloxone L-Naloxone Naloxona Nalossone Naloxonum 17-Allyl-3,14-dihydroxy-4,5alpha-epoxymorphinan-6-one
n3:toxicity
LD50, IV administration, mouse = 150 ± 5 mg/kg; LD50, IV administration, rat = 109 ± 4 mg/kg;
n3:volumeOfDistribution
Following parenteral administration naloxone hydrochloride is rapidly distributed in the body. Naloxone is also very lipophillic and easily crosses the blood-brain-barrier. It can also cross the placenta.
n18:hasAHFSCode
n30:28-10-00
n3:mixture
n15:271B5049-363D-11E5-9242-09173F13E4C5 n15:271B504C-363D-11E5-9242-09173F13E4C5 n15:271B504A-363D-11E5-9242-09173F13E4C5 n15:271B504B-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
Plasma protein binding occurs but is relatively weak. Plasma albumin is the major binding constituent but significant binding of naloxone also occurs to plasma constituents other than albumin.
n3:salt
n3:synthesisReference
Bianca Brogmann, Silke Muhlau, Christof Spitzley, "Pharmaceutical preparation containing oxycodone and naloxone." U.S. Patent US20050245556, issued November 03, 2005.
n11:hasConcept
n12:M0014441
foaf:page
n6:naloxone.html n31:naloxone.htm
n3:IUPAC-Name
n4:271B506E-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5074-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5073-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5070-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5071-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5072-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5084-363D-11E5-9242-09173F13E4C5 n4:271B506C-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5086-363D-11E5-9242-09173F13E4C5 n4:271B506A-363D-11E5-9242-09173F13E4C5 n4:271B506D-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B506B-363D-11E5-9242-09173F13E4C5
n18:hasATCCode
n19:V03AB15
n3:H-Bond-Acceptor-Count
n4:271B507A-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B507B-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5075-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5076-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5078-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5077-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5079-363D-11E5-9242-09173F13E4C5
n3:absorption
Well absorbed following intramuscular injection.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
465-65-6
n3:category
n3:containedIn
n32:271B5064-363D-11E5-9242-09173F13E4C5 n32:271B5062-363D-11E5-9242-09173F13E4C5 n32:271B5063-363D-11E5-9242-09173F13E4C5 n32:271B5060-363D-11E5-9242-09173F13E4C5 n32:271B5061-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B5080-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5082-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5083-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B5085-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B507F-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B507E-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5081-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B506F-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B507C-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B507D-363D-11E5-9242-09173F13E4C5